Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients with Versus Without Chronic Kidney Disease

Nishank Jain, Xilong Li, Beverley Adams-Huet, Ravi Sarode, Robert D. Toto, Subhash Banerjee, S. Susan Hedayati

Research output: Contribution to journalArticle

5 Scopus citations


Thrombotic events while receiving antiplatelet agents (APAs) are more common in subjects with versus without chronic kidney disease (CKD). Data on antiplatelet effects of APA in CKD are scarce and limited by lack of baseline platelet function before APA treatment. We hypothesized subjects with stages 4 to 5 CKD versus no CKD have greater baseline platelet aggregability and respond poorly to aspirin and clopidogrel. In a prospective controlled study, we measured whole blood platelet aggregation (WBPA) in 28 CKD and 16 non-CKD asymptomatic stable outpatients not on APA, frequency-matched for age, gender, obesity, and diabetes mellitus. WBPA was remeasured after 2 weeks of each aspirin and aspirin plus clopidogrel. The primary outcome was percent inhibition of platelet aggregation (IPA) from baseline. The secondary outcome was residual platelet aggregability (RPA; proportion with

Original languageEnglish (US)
Pages (from-to)656-663
Number of pages8
JournalAmerican Journal of Cardiology
Issue number4
StatePublished - Feb 15 2016


ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this